Olaparib-induced adaptive response Is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition

Pingping Fang, Jill A. Madden, Lisa Neums, Ryan K. Moulder, M. Laird Forrest, Jeremy Chien

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

FOXM1 transcription factor network is activated in over 84% of cases in high-grade serous ovarian cancer (HGSOC), and FOXM1 upregulates the expression of genes involved in the homologous recombination (HR) DNA damage and repair (DDR) pathway. However, the role of FOXM1 in PARP inhibitor response has not yet been studied. This study demonstrates that PARP inhibitor (PARPi), olaparib, induces the expression and nuclear localization of FOXM1. On the basis of ChIPqPCR, olaparib enhances the binding of FOXM1 to genes involved in HR repair. FOXM1 knockdown by RNAi or inhibition by thiostrepton decreases FOXM1 expression, decreases the expression of HR repair genes, such as BRCA1 and RAD51, and enhances sensitivity to olaparib. Comet and PARP trapping assays revealed increases in DNA damage and PARP trapping in FOXM1-inhibited cells treated with olaparib. Finally, thiostrepton decreases the expression of BRCA1 in rucaparib-resistant cells and enhances sensitivity to rucaparib. Collectively, these results identify that FOXM1 plays an important role in the adaptive response induced by olaparib and FOXM1 inhibition by thiostrepton induces "BRCAness" and enhances sensitivity to PARP inhibitors. Implications: FOXM1 inhibition represents an effective strategy to overcome resistance to PARPi, and targeting FOXM1-mediated adaptive pathways may produce better therapeutic effects for PARP inhibitors. Mol Cancer Res; 16(6); 961-73.

Original languageEnglish (US)
Pages (from-to)961-973
Number of pages13
JournalMolecular Cancer Research
Volume16
Issue number6
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Thiostrepton
Recombinational DNA Repair
DNA Damage
Therapeutic Uses
RNA Interference
Ovarian Neoplasms
Genes
Transcription Factors
Up-Regulation
olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Gene Expression
Neoplasms
rucaparib

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Olaparib-induced adaptive response Is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition. / Fang, Pingping; Madden, Jill A.; Neums, Lisa; Moulder, Ryan K.; Forrest, M. Laird; Chien, Jeremy.

In: Molecular Cancer Research, Vol. 16, No. 6, 01.06.2018, p. 961-973.

Research output: Contribution to journalArticle

Fang, Pingping ; Madden, Jill A. ; Neums, Lisa ; Moulder, Ryan K. ; Forrest, M. Laird ; Chien, Jeremy. / Olaparib-induced adaptive response Is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition. In: Molecular Cancer Research. 2018 ; Vol. 16, No. 6. pp. 961-973.
@article{0a2ce29ca449408fbebe1623cacee1e0,
title = "Olaparib-induced adaptive response Is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition",
abstract = "FOXM1 transcription factor network is activated in over 84{\%} of cases in high-grade serous ovarian cancer (HGSOC), and FOXM1 upregulates the expression of genes involved in the homologous recombination (HR) DNA damage and repair (DDR) pathway. However, the role of FOXM1 in PARP inhibitor response has not yet been studied. This study demonstrates that PARP inhibitor (PARPi), olaparib, induces the expression and nuclear localization of FOXM1. On the basis of ChIPqPCR, olaparib enhances the binding of FOXM1 to genes involved in HR repair. FOXM1 knockdown by RNAi or inhibition by thiostrepton decreases FOXM1 expression, decreases the expression of HR repair genes, such as BRCA1 and RAD51, and enhances sensitivity to olaparib. Comet and PARP trapping assays revealed increases in DNA damage and PARP trapping in FOXM1-inhibited cells treated with olaparib. Finally, thiostrepton decreases the expression of BRCA1 in rucaparib-resistant cells and enhances sensitivity to rucaparib. Collectively, these results identify that FOXM1 plays an important role in the adaptive response induced by olaparib and FOXM1 inhibition by thiostrepton induces {"}BRCAness{"} and enhances sensitivity to PARP inhibitors. Implications: FOXM1 inhibition represents an effective strategy to overcome resistance to PARPi, and targeting FOXM1-mediated adaptive pathways may produce better therapeutic effects for PARP inhibitors. Mol Cancer Res; 16(6); 961-73.",
author = "Pingping Fang and Madden, {Jill A.} and Lisa Neums and Moulder, {Ryan K.} and Forrest, {M. Laird} and Jeremy Chien",
year = "2018",
month = "6",
day = "1",
doi = "10.1158/1541-7786.MCR-17-0607",
language = "English (US)",
volume = "16",
pages = "961--973",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Olaparib-induced adaptive response Is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition

AU - Fang, Pingping

AU - Madden, Jill A.

AU - Neums, Lisa

AU - Moulder, Ryan K.

AU - Forrest, M. Laird

AU - Chien, Jeremy

PY - 2018/6/1

Y1 - 2018/6/1

N2 - FOXM1 transcription factor network is activated in over 84% of cases in high-grade serous ovarian cancer (HGSOC), and FOXM1 upregulates the expression of genes involved in the homologous recombination (HR) DNA damage and repair (DDR) pathway. However, the role of FOXM1 in PARP inhibitor response has not yet been studied. This study demonstrates that PARP inhibitor (PARPi), olaparib, induces the expression and nuclear localization of FOXM1. On the basis of ChIPqPCR, olaparib enhances the binding of FOXM1 to genes involved in HR repair. FOXM1 knockdown by RNAi or inhibition by thiostrepton decreases FOXM1 expression, decreases the expression of HR repair genes, such as BRCA1 and RAD51, and enhances sensitivity to olaparib. Comet and PARP trapping assays revealed increases in DNA damage and PARP trapping in FOXM1-inhibited cells treated with olaparib. Finally, thiostrepton decreases the expression of BRCA1 in rucaparib-resistant cells and enhances sensitivity to rucaparib. Collectively, these results identify that FOXM1 plays an important role in the adaptive response induced by olaparib and FOXM1 inhibition by thiostrepton induces "BRCAness" and enhances sensitivity to PARP inhibitors. Implications: FOXM1 inhibition represents an effective strategy to overcome resistance to PARPi, and targeting FOXM1-mediated adaptive pathways may produce better therapeutic effects for PARP inhibitors. Mol Cancer Res; 16(6); 961-73.

AB - FOXM1 transcription factor network is activated in over 84% of cases in high-grade serous ovarian cancer (HGSOC), and FOXM1 upregulates the expression of genes involved in the homologous recombination (HR) DNA damage and repair (DDR) pathway. However, the role of FOXM1 in PARP inhibitor response has not yet been studied. This study demonstrates that PARP inhibitor (PARPi), olaparib, induces the expression and nuclear localization of FOXM1. On the basis of ChIPqPCR, olaparib enhances the binding of FOXM1 to genes involved in HR repair. FOXM1 knockdown by RNAi or inhibition by thiostrepton decreases FOXM1 expression, decreases the expression of HR repair genes, such as BRCA1 and RAD51, and enhances sensitivity to olaparib. Comet and PARP trapping assays revealed increases in DNA damage and PARP trapping in FOXM1-inhibited cells treated with olaparib. Finally, thiostrepton decreases the expression of BRCA1 in rucaparib-resistant cells and enhances sensitivity to rucaparib. Collectively, these results identify that FOXM1 plays an important role in the adaptive response induced by olaparib and FOXM1 inhibition by thiostrepton induces "BRCAness" and enhances sensitivity to PARP inhibitors. Implications: FOXM1 inhibition represents an effective strategy to overcome resistance to PARPi, and targeting FOXM1-mediated adaptive pathways may produce better therapeutic effects for PARP inhibitors. Mol Cancer Res; 16(6); 961-73.

UR - http://www.scopus.com/inward/record.url?scp=85048234059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048234059&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-17-0607

DO - 10.1158/1541-7786.MCR-17-0607

M3 - Article

C2 - 29545475

AN - SCOPUS:85048234059

VL - 16

SP - 961

EP - 973

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 6

ER -